Clinical trials: Spondylitis, Ankylosing
Osteoarthritis, Rheumatoid Arthritis
Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)
The primary objective of this cross-sectional observational real life study is to investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID associated GI Ulcers to patients prescribed a NSAID.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- CONVOY (NCT01519375)
- Where
- 8 sites in Sweden
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Spondylitis, Ankylosing
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS).
- Trial name
- NCT01208207
- Testing
- Part I - etoricoxib 60 mg, Part I - etoricoxib 90 mg, Part I- naproxen 1000 mg
- Volunteers
- 1,015 people
- Sponsor
- Organon and Co
Ankylosing Spondylitis
Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)
This study is a population-based cohort of patients with ankylosing spondylitis (AS) from general medical practices in the UK, France, and Germany with a nested case control component to assess associations between drug exposures…
- Trial name
- NCT01077843
- Testing
- Etoricoxib, Other Cox-2 inhibitors, Other Non-selective NSAIDs
- Volunteers
- 27,381 people
- Sponsor
- Organon and Co
Ankylosing Spondylitis
A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)
This study will evaluate the effect and safety of 608 in patients with AS.
- Trial name
- NCT06242652
- Testing
- 608 Dose A, 608 Dose B, 608 Dose C
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ankylosing Spondylitis
Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
This study assessed the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to secukinumab and evaluated to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be…
- Trial name
- ASTRUM (NCT02763046)
- Testing
- Secukinumab (AIN457) 150 mg s.c.
- Where
- 39 sites in Germany
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis
The objective of this study was to evaluate the safety and efficacy of multiple doses of LNK01001 monotherapy versus placebo in the treatment of adults with active Ankylosing Spondylitis
- Trial name
- NCT06085534
- Testing
- LNK01001
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Ankylosing Spondylitis
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis
- Trial name
- NCT00195819
- Testing
- adalimumab (D2E7)
- Where
- 9 sites in Canada
- Volunteers
- 82 people
- Sponsor
- Abbott
Ankylosing Spondylitis
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal…
- Trial name
- NCT02750592
- Testing
- Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
- Where
- 10 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Ankylosing Spondylitis
bIosimilar of aDalimumab, an European evAluation
The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn Disease
- Trial name
- IDEA (NCT05190484)
- Volunteers
- 1,050 people
- Sponsor
- Fresenius Kabi
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis
- Trial name
- REMission (NCT00727298)
- Testing
- Infliximab
- Volunteers
- 4,485 people
- Sponsor
- Merck Sharp & Dohme LLC
Ankylosing Spondylitis
International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis
BCD-085-5 is an International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17.
- Trial name
- NCT03447704
- Testing
- BCD-085
- Where
- 7 sites in Russia
- Volunteers
- 228 people
- Sponsor
- Biocad
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
The purpose of this study is to assess whether or not adalimumab (Humira®) can influence pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) with or without…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01273519
- Where
- 15 sites in Austria
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis
A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.
A study of the safety and efficacy of Infliximab (Remicade) versus placebo in subjects with Ankylosing Spondylitis
- Trial name
- NCT00207701
- Testing
- infliximab
- Volunteers
- 279 people
- Sponsor
- Centocor, Inc.
Active Ankylosing Spondylitis
Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study. The study was divided into three stages, including screening period(4-week), treatment period(16-week) and observation period.
- Trial name
- NCT05407246
- Testing
- Hemay005
- Where
- 11 sites in China
- Volunteers
- 90 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Osteoarthritis, Rheumatoid Arthritis
Web-based Support to Manage Arthritis Pain
Development of an interactive, online pain self-management program for adults who suffer from pain associated with osteoarthritis, rheumatoid arthritis, Ankylosing spondylitis, and other arthritic conditions (e.g., psoriatic…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
- Trial name
- NCT01463189
- Testing
- painACTION: Arthritis
- Where
- United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Inflexxion, Inc.
Ankylosing Spondylitis, Arthritis, Psoriatic
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
This is a Phase 4 open label, non-interventional, multi-center study to evaluate the safety of Enbrel (etanercept) treatment in patients receiving etanercept 25mg sc twice weekly or 50mg of etanercept once weekly.
- Conditions
- Ankylosing Spondylitis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Spondylitis, Ankylosing
- Trial name
- NCT00273858
- Testing
- There is no Intervention. The study is observational.
- Where
- 9 sites in Greece
- Volunteers
- 880 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Spondylitis, Ankylosing
Extension in AS: Sustainability of Benefits, Safety and Tolerability
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as…
- Trial name
- MEASURE 1 ext (NCT01863732)
- Testing
- Secukinumab
- Where
- 56 sites in United States, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.
- Trial name
- NCT00544557
- Testing
- Etanercept
- Where
- Germany
- Volunteers
- 1,715 people
- Sponsor
- Pfizer
Osteoarthritis, Rheumatoid Arthritis
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
The most common pain-relievers used by patients with rheumatic disorders are called non-steroidal anti-inflammatory drugs (NSAIDs).
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- CHARACTERIZE (NCT01511926)
- Where
- 96 sites in Belgium, Finland and 6 more
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca